Gotoh Mituhiro, Mizuno Kenji, Ono Yoshiaki, Takahashi Michihiko
Department of Internal Medicine, Fukushima Rosai Hospital, Iwaki, Japan.
Fukushima J Med Sci. 2011;57(1):19-27. doi: 10.5387/fms.57.19.
Although several studies have reported a lower risk of osteoporotic fracture in hypercholesterolemic patients (WHO IIa) treated with statin, longitudinal studies on the effects of statins on bone are lacking. The aim of the present study was to evaluate bone mineral density (BMD) and bone turnover changes induced by 3-year fluvastatin treatment in postmenopausal women. Twenty-eight consecutive postmenopausal non-diabetic, normotensive hypercholesterolemic women (64.0±3.6 years) were treated for 36 months with 30 mg/day fluvastatin and 28 non-diabetic, normotensive normocholesterolemic age- and body mass index-matched postmenopausal women served as the control subjects. The result revealed a significant increase of the BMD as compared with the level at the base line (p< 0.001) in the fluvastairn-treated group, from 6 months on ward after the start treatment. Significant differences of the BMD were found between the controls and fluvastatin-treated group (p< 0.001) were at 6, 12, 24 and 36 months after the start of the study. In conclusion our results, although obtained small sample of postmenopausal hypercholesterolemic women, suggest a probable favorable effect of fluvastatin on bone formation and BMD.
尽管有几项研究报告称，接受他汀类药物治疗的高胆固醇血症患者（世界卫生组织IIa型）发生骨质疏松性骨折的风险较低，但关于他汀类药物对骨骼影响的纵向研究却很缺乏。本研究的目的是评估氟伐他汀治疗3年对绝经后女性骨密度（BMD）和骨转换的影响。连续28名绝经后非糖尿病、血压正常的高胆固醇血症女性（64.0±3.6岁）接受了为期36个月、每日30毫克氟伐他汀的治疗，另外28名年龄和体重指数匹配的绝经后非糖尿病、血压正常、胆固醇正常的女性作为对照。结果显示，与基线水平相比，氟伐他汀治疗组从开始治疗6个月后骨密度显著增加（p<0.001）。在研究开始后的6、12、24和36个月时，对照组与氟伐他汀治疗组之间的骨密度存在显著差异（p<0.001）。总之，我们的研究结果虽然是基于少量绝经后高胆固醇血症女性样本得出的，但表明氟伐他汀可能对骨形成和骨密度有有利影响。
